One common approach is to focus on processes known to be associated with anticancer immunity (e.g., cytolytic activity of tumor-infiltrating lymphocytes,14 presence of tertiary lymphoid structures,15 and interferon-gamma [IFN-γ] signaling16) and derive a related gene signature that can be used to predict patients’ response to immunotherapy from pre-therapy RNA-seq data. The gene discussed is IFNG; the disease is neoplasm.